

University of Groningen

## Meta-analysis of genome-wide association studies reveals genetic overlap between Hodgkin lymphoma and multiple sclerosis

Khankhanian, Pouya; Cozen, Wendy; Himmelstein, Daniel S.; Madireddy, Lohith; Din, Lennox; van den Berg, A.; Matsushita, Takuya; Glaser, Sally L.; More, Jayaji M.; Smedby, Karin E.

*Published in:*  
International Journal of Epidemiology

*DOI:*  
[10.1093/ije/dyv364](https://doi.org/10.1093/ije/dyv364)

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*  
Publisher's PDF, also known as Version of record

*Publication date:*  
2016

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Khankhanian, P., Cozen, W., Himmelstein, D. S., Madireddy, L., Din, L., van den Berg, A., ... Hjalgrim, H. (2016). Meta-analysis of genome-wide association studies reveals genetic overlap between Hodgkin lymphoma and multiple sclerosis. *International Journal of Epidemiology*, 45(3), 728-740. DOI: 10.1093/ije/dyv364

**Copyright**

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

**Take-down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*



Neurological Disorders and Cancer

# Meta-analysis of genome-wide association studies reveals genetic overlap between Hodgkin lymphoma and multiple sclerosis

Pouya Khankhanian,<sup>1,2</sup> Wendy Cozen,<sup>3</sup> Daniel S Himmelstein,<sup>2</sup> Lohith Madireddy,<sup>2</sup> Lennox Din,<sup>2</sup> Anke van den Berg,<sup>4</sup> Takuya Matsushita,<sup>2</sup> Sally L Glaser,<sup>5</sup> Jayaji M Moré,<sup>2</sup> Karin E Smedby,<sup>6</sup> Sergio E Baranzini,<sup>2</sup> Thomas M Mack,<sup>3</sup> Antoine Lizée,<sup>2</sup> Silvia de Sanjosé,<sup>7</sup> Pierre-Antoine Gourraud,<sup>2</sup> Alexandra Nieters,<sup>8</sup> Stephen L Hauser,<sup>2</sup> Pierluigi Cocco,<sup>9</sup> Marc Maynadié,<sup>10</sup> Lenka Foretová,<sup>11</sup> Anthony Staines,<sup>12</sup> Manon Delahaye-Sourdeix,<sup>13</sup> Dalin Li,<sup>3</sup> Smita Bhatia,<sup>14</sup> Mads Melbye,<sup>15</sup> Kenan Onel,<sup>16</sup> Ruth Jarrett,<sup>17</sup> James D McKay,<sup>13</sup> Jorge R Oksenberg<sup>2</sup> and Henrik Hjalgrim<sup>15\*</sup>

<sup>1</sup>Center for Neuroengineering and Therapeutics at the University of Pennsylvania, Philadelphia, PA, USA, <sup>2</sup>University of California, San Francisco, CA, USA, <sup>3</sup>University of Southern California, Los Angeles, CA, USA, <sup>4</sup>University Medical Center, Groningen, The Netherlands, <sup>5</sup>Cancer Prevention Institute of California, Fremont, CA, USA, <sup>6</sup>Karolinska Institute, Stockholm, Sweden, <sup>7</sup>Catalan Institute of Oncology, L'Hospitalet de Llobregat, Catalonia, Spain, <sup>8</sup>University Medical Center Freiburg, Freiburg, Germany, <sup>9</sup>University of Cagliari, Cagliari, Sardinia, Italy, <sup>10</sup>Centre Hospitalier Universitaire de Dijon, Dijon, France, <sup>11</sup>Masaryk Memorial Cancer Institute, Brno, Czech Republic, <sup>12</sup>University College Dublin, Dublin, Ireland, <sup>13</sup>International Agency for Research on Cancer, Lyon, France, <sup>14</sup>City of Hope National Medical Center, Duarte, CA, USA, <sup>15</sup>Statens Serum Institut, Copenhagen S, Denmark, <sup>16</sup>University of Chicago, Chicago, IL, USA, <sup>17</sup>MRC, University of Glasgow Centre for Virus Research, Glasgow, UK

\*Corresponding author. Statens Serum Institut, 5 Artillerivej, DK-2300 Copenhagen S, Denmark. E-mail: HHJ@ssi.dk

Accepted 18 December 2015

## Abstract

**Background:** Based on epidemiological commonalities, multiple sclerosis (MS) and Hodgkin lymphoma (HL), two clinically distinct conditions, have long been suspected to be aetiologically related. MS and HL occur in roughly the same age groups, both are associated with Epstein-Barr virus infection and ultraviolet (UV) light exposure, and they cluster mutually in families (though not in individuals). We speculated if in addition to sharing environmental risk factors, MS and HL were also genetically related. Using data from genome-wide association studies (GWAS) of 1816 HL patients, 9772 MS patients and 25 255 controls, we therefore investigated the genetic overlap between the two diseases.

**Methods:** From among a common denominator of 404 K single nucleotide polymorphisms (SNPs) studied, we identified SNPs and human leukocyte antigen (HLA) alleles

independently associated with both diseases. Next, we assessed the cumulative genome-wide effect of MS-associated SNPs on HL and of HL-associated SNPs on MS. To provide an interpretational frame of reference, we used data from published GWAS to create a genetic network of diseases within which we analysed proximity of HL and MS to autoimmune diseases and haematological and non-haematological malignancies.

**Results:** SNP analyses revealed genome-wide overlap between HL and MS, most prominently in the HLA region. Polygenic HL risk scores explained 4.44% of HL risk (Nagelkerke  $R^2$ ), but also 2.36% of MS risk. Conversely, polygenic MS risk scores explained 8.08% of MS risk and 1.94% of HL risk. In the genetic disease network, HL was closer to autoimmune diseases than to solid cancers.

**Conclusions:** HL displays considerable genetic overlap with MS and other autoimmune diseases.

#### Key Messages

- Epidemiological similarities have suggested common aetiologies for Hodgkin lymphoma and multiple sclerosis.
- Consistent with this hypothesis, detailed analyses reveal considerable genetic overlap between Hodgkin lymphoma and multiple sclerosis.
- Genetically, Hodgkin lymphoma lies closer to autoimmune diseases than to solid cancers.

## Introduction

Hodgkin lymphoma (HL) is an immunologically active malignant neoplasm of B cells in a heterogeneous reactive cellular infiltrate.<sup>1</sup> HL is roughly equally common in men and women, and in socioeconomically affluent populations HL occurrence displays a bimodal age distribution, with separate peaks in younger adults (15–34 years old) and older adults (over 50 years old).<sup>2–4</sup> In socioeconomically deprived settings, in contrast, there is no young adult HL incidence peak, but rather one among children.<sup>5</sup>

Multiple sclerosis (MS) is a debilitating disease of the central nervous system (CNS) characterized by chronic polycellular inflammation (including T cells, monocytes and B cells), myelin loss, gliosis, axonal and oligodendrocyte pathology and accumulation of progressive neurological disability.<sup>6</sup> Onset is typically between the ages of 20 to 40 years, with a female to male ratio of three to one.<sup>6</sup>

Based on conspicuous epidemiological similarities between the two conditions, e.g. regarding age patterns and geographical distributions, Newell in 1970 proposed that HL and MS were somehow aetiologically related.<sup>7</sup> Subsequent epidemiological studies have tested this hypothesis by assessing clustering of HL with MS in individuals and in families. Whereas previous studies generally suggest that patients suffering from either condition are not at increased risk of the other,<sup>8–16</sup> two partially overlapping investigations have reported mutual clustering of the two diseases among first-degree relatives.<sup>17,18</sup>


Familial clustering of HL and MS may reflect shared environmental and genetic risk factors. Evidence implicates infection with the Epstein-Barr virus (EBV)<sup>19–22</sup> and levels of ultraviolet light exposure<sup>23,24</sup> in the pathogenesis of the roughly one-third of HL cases that harbour EBV in the malignant cells (EBV-positive HL), as well as in the pathogenesis of MS. Moreover, common genetic risk factors have emerged in HL and MS.<sup>25–28</sup> For example, HLA-A\*02 appears to be associated with a decreased risk of both MS<sup>29</sup> and EBV-positive HL,<sup>30,31</sup> and DNA variants in the *Relish* oncogene (*REL*, a member of the NF-kappaB transcription factor family) have been associated with both MS<sup>32</sup> and the EBV-negative subset of HL.<sup>25</sup> This suggests that the relationship between HL and MS is not limited to either EBV-positive or EBV-negative HL.

Unveiling of aetiological commonalities for HL and MS could contribute to the understanding of their pathogenesis and might even have clinical implications. We therefore combined data from previous genome-wide association studies (GWAS) of MS<sup>28</sup> and HL<sup>26,27,33,34</sup> and evaluated the genetic overlap between the two diseases.

## Methods

### Overview

Analysis was performed on a total of 1816 HL patients, 9772 MS patients and 25 255 controls, using 404 K single



**Figure 1.** Study design and data analysis procedures. Results from previously reported genome-wide associations studies (GWAS) of Hodgkin lymphoma (HL) and multiple sclerosis (MS) were used to assess genetic overlap between the two diseases. Single nucleotide polymorphisms (SNPs) independently associated with both HL and MS were identified, and disease-specific polygenic risk scores were compared in HL cases, MS cases and healthy controls. Protein-interaction network-based pathway analysis (PINBPA) was performed on the intersection of nominally associated ( $P < 0.05$ ) SNPs in HL and MS and gene ontology (GO) analysis was performed to identify common genetic pathways. Genetic similarity between HL and MS was further evaluated in the context of other immune diseases, haematological malignancies and solid cancers by constructing a diseaseome using data from previously reported GWAS.

nucleotide polymorphisms (Figure 1). We first sought to identify single nucleotide polymorphisms (SNPs) and HLA alleles that associated independently with both diseases. Next, we calculated polygenic risk scores to assess the cumulative genome-wide effect of MS-associated SNPs on HL, and of HL-associated SNPs on MS. To describe the overlap between HL and MS, we performed a protein interaction network-based pathway analysis (PINBPA) on associated genes from each disease, and then investigated the intersection of networks for biological relevance. To place the genetic similarity between HL and MS in context, we used data from previously reported GWAS to create a diseaseome: a network of diseases. Within the diseaseome, we analysed proximity of HL and MS to autoimmune diseases and haematological and non-haematological malignancies ('solid' cancers).

### HL and MS dataset characteristics

The HL<sup>26,27,33,34</sup> and MS<sup>28</sup> cohorts have previously been described in detail. For MS, data from the Wellcome Trust Case Control Consortium 2 meta-analysis project totalled 9772 cases and 17 376 controls. Individuals in this dataset were of European descent and originated from 15 geographical regions, including the USA, Australia, New Zealand and

numerous European countries. Included in this dataset were summary-level association results for a total of 464 434 SNPs.

For HL, data from a recent meta-analysis of three GWAS studies consisted of 1816 cases and 7879 controls.<sup>34</sup> Individuals in this dataset were of European descent and originated from locations in the USA and Europe. Summary-level meta-association results were included for a total of 1 036 304 SNPs. The cases were subdivided into nodular lymphocytic predominant and classical HL, and classical HL further divided into subgroups by EBV tumour status (EBV-positive and EBV-negative) as determined by immunohistochemistry or *in situ* hybridization as previously described<sup>27</sup> and histology [mixed cellularity (MC), nodular sclerosis (NS) and other or unspecified], when such data were available. Summary characteristics are shown in Table S1 (available as Supplementary data at *IJE* online).

The HL and MS datasets were merged (by rsID), giving a final dataset containing summary-level results for 404 069 overlapping SNPs.

### Overlap between diseases: SNP-level

We followed a procedure similar to that used in other meta-analyses of complex genetic diseases.<sup>35</sup> To assess genetic

overlap between HL and MS, we sought SNPs that associated independently with both diseases. We identified top ( $P$ -value  $< 5 \times 10^{-8}$ ) independent ( $r^2 < 0.1$  in CEU) MS-susceptibility SNPs, and determined how many of these SNPs are associated with HL after correction by Benjamini-Hochberg method (corrected  $P$ -value  $< 0.05$ ). The process was repeated for increasingly liberal values of the  $P$ -value threshold for defining MS susceptibility SNPs (ranging from  $P$ -value  $< 5 \times 10^{-8}$  to  $P$ -value  $< 5 \times 10^{-2}$ ). Corresponding analysis was repeated after switching roles for HL and MS. The HLA region was analysed in further detail using imputed classical HLA alleles (see [Supplementary methods](#) for details, available as [Supplementary data](#) at *IJE* online).

Supplementary analysis considered MS SNPs on subsets of the HL dataset as defined by tumour EBV status (EBV-positive HL and EBV-negative HL), tumour histology [nodular sclerosis (NS), mixed cellularity (MC)], or tumour histology combined with age (NS among 15-35 year olds), in order to explore possible heterogeneity among the HL samples.

### Overlap between diseases: polygenic risk

Polygenic risk scores were calculated to test the cumulative effect of SNPs associated with HL on MS and vice versa, as described in detail in other complex genetic diseases.<sup>32,35-37</sup> For each trait (HL and MS), sets of top independent SNPs were chosen as described above. Multiple sclerosis genetic burden (MSGB) and Hodgkin lymphoma genetic burden (HLGB) were calculated for each individual: the weighted sum of the number of risk alleles at each SNP in the set, weighted by the log-odds ratio of association for each SNP. We assessed the ability of MSGB to distinguish HL cases from controls and the ability of HLGB to distinguish MS cases from controls using the Nagelkerke's  $R^2$  (note that the  $P$ -values of the linear regression models will largely be driven by large sample sizes, and the biological significance lies in the  $R^2$  value rather than the  $P$ -value). This analysis was repeated for subgroups of HL (EBV-positive, EBV-negative, MC and NS).

### Protein interaction network-based pathway analysis (PINBPA)

To visualize the sets of interacting genes found to associate with both HL and MS, a protein interaction network-based pathway analysis (PINBPA) was performed using methods described previously.<sup>32</sup> Sub-networks of aggregate score of three or greater were chosen as associated. Network discovery was performed independently in HL and MS, networks of score three or greater being chosen as associated. The intersection of the HL and MS networks

was visualized. Gene ontology analysis was performed on genes in this intersection.

### Diseasome analysis

To further assess genetic similarity between HL and MS, a representation of the human diseasome (network of diseases)<sup>38,39</sup> was constructed in which diseases (nodes) were connected by the extent of their shared genetic aetiology (edges)<sup>40,41</sup> as reported by the GWAS catalogue<sup>42</sup>. This network is termed the diseasome. Diseases were manually classified as haematological malignancies, solid cancers or autoimmune diseases. Pairwise proximity measures between diseases were calculated as described in [Supplementary methods](#). Relative distances between haematological malignancies, solid cancers, and auto-immune diseases were tested by t-test.

## Results

### SNP and HLA allele overlap between HL and MS

We identified SNPs associated with MS across multiple  $P$ -value thresholds ranging from  $P$ -value  $< 5 \times 10^{-8}$  to  $P$ -value  $< 5 \times 10^{-2}$ . Among these SNPs, we then identified those that were also associated with HL (FDR  $< 0.05$ ; false discovery rate with Benjamini-Hochberg adjustment of  $P$ -values for the total number of SNPs tested at each threshold) ([Table 1](#)).

At a threshold of  $P$ -value  $< 5 \times 10^{-8}$ , 429 SNPs were associated with MS; 36 of these 429 were independent ( $r^2 < 0.1$ ), and three of these 36 were associated with HL at an FDR  $< 0.05$  (Benjamini-Hochberg correction for 36 tests), summarized in row 1 of [Table 1](#). Panel 1 of [Table 1](#) shows results for other  $P$ -value thresholds and panel 2 shows results when top HL SNPs were tested for association in MS. SNPs found to be overlapping (final column of [Table 1](#)) are described in [Table 2](#) (after HLA is removed). While the actual number and proportion of overlapping SNPs varied by the  $P$ -value threshold, the majority of overlapping SNPs belonged to genes in the HLA region of chromosome 6; however, several mutually associated non-HLA SNPs were also detected ([Table 2](#); [Figure S1](#), [Table S2](#), available as [Supplementary data](#) at *IJE* online). It should be noted that the direction of association was not taken into account in this analysis, which reveals only shared genetic risk loci (see genetic burden analysis below, which accounts for direction of association).

The SNP-level overlap between diseases was repeated for each HL subgroup: MS versus EBV-positive HL, MS versus EBV-negative HL, MS versus NS-HL, MS versus NS-HL in



**Table 1.**Overlap of associated SNPs in HL and MS at increasing thresholds

Top MS-associated SNPs in HL			
MS <i>P</i> -value threshold	Number of SNPs associated with MS	Number of independent MS SNPs	Number of independent MS SNPs also associated with HL (FDR < 0.05)
$5 \times 10^{-8}$	429	36	3
$5 \times 10^{-7}$	497	50	4
$5 \times 10^{-6}$	601	76	6
$5 \times 10^{-5}$	825	138	4
$5 \times 10^{-4}$	1422	386	3
0.005	4317	1715	3
0.05	24225	9107	2
Top HL-associated SNPs in MS			
HL <i>P</i> -value threshold	Number of SNPs associated with HL	Number of independent HL SNPs	Number of independent HL SNPs also associated with MS (FDR < 0.05)
$5 \times 10^{-8}$	11	6	5
$5 \times 10^{-7}$	23	12	9
$5 \times 10^{-6}$	37	17	12
$5 \times 10^{-5}$	60	30	15
$5 \times 10^{-4}$	291	165	19
0.005	2053	1155	32
0.05	17541	7196	36

In the upper panel, top MS-associated SNPs at a given *P*-value threshold (column 1) are counted (column 2), thinned to include only independent SNPs (column 3). Independent MS SNPs are tested in HL for association; the number of independent SNPs which pass FDR < 0.05 in HL is shown (column 4). In the lower panel, the top HL SNPs are counted, thinned and tested for association with MS.

LD, linkage disequilibrium; FDR, Benjamini-Hochberg false discovery rate, adjusted for the total number of independent SNPs tested.

15 to 35-year-olds and MS versus MC-HL. These analyses revealed no major differences between HL subgroups.

Given the strong genetic overlap at HLA, HLA alleles were imputed from SNP information via the HIBAG algorithm (see [Supplementary methods](#), available as [Supplementary data](#) at *IJE* online). [Figure 2](#) demonstrates overlap between risk alleles for EBV-negative HL and risk alleles for MS, as well as overlap between protective alleles for EBV-negative HL and protective alleles for MS. In contrast, there is no overlap between risk alleles for EBV-positive HL and risk alleles for MS, whereas there is overlap between protective alleles for EBV-positive HL and protective alleles for MS. [Table S3](#) (available as [Supplementary data](#) at *IJE* online) provides details of HLA allelic *P*-values and odds ratios in each disease. Analysis of NS-HL revealed a pattern similar to EBV-negative HL.

### Polygenic risk overlap between diseases

To assess the extent of genetic risk overlap between HL and MS at the genome-wide level (including HLA), polygenic risk scores, termed MS genetic burden (MSGB) and HL genetic burden (HLGB) were calculated in all cases of MS, all cases of HL and all controls used in the MS study.

[Figure 3A](#) shows the MSGB (y-axis) in each population. As expected, the MSGB was higher in MS cases than in controls ( $P$ -value <  $1.0 \times 10^{-200}$ ) and explained 8.08% of the risk for MS (Nagelkerke's  $R^2$ ). However, the MSGB was also higher in HL cases than in controls ( $P$ -value <  $2.8 \times 10^{-35}$ ) and explained 1.94% of the risk for HL. [Figure 3B](#) shows the HLGB (y-axis) in each population. As expected, the HLGB was higher in HL cases than in controls ( $P$ -value <  $2.8 \times 10^{-81}$ ) and explained 4.44% of the risk for HL. However, HLGB was also higher in MS cases compared with controls ( $P$ -value <  $2.0 \times 10^{-121}$ ) and explained 2.36% of the MS risk. Results shown here use a threshold of  $P$ -value <  $5 \times 10^{-6}$  for including SNPs in the polygenic risk score, which results in 76 independent SNPs used for MSGB and 17 independent SNPs used for HLGB. Similar results held true at other *P*-value thresholds. We observed no major differences among HL subgroups.

### Pathway analysis

To generate hypotheses about potential functional pathways that are common to HL and MS, we carried out PINBPA in each independent dataset based on the

**Table 2.** Non-HLA SNPs associated with both HL and MS at decreasing thresholds

MS <i>P</i> -value threshold	$5 \times 10^{-8}$	$5 \times 10^{-7}$	$5 \times 10^{-6}$	$5 \times 10^{-5}$	$5 \times 10^{-4}$	0.005	0.05	CHR	Position
rs12746893	HL	HL	HL	HL				1	92 983 464
rs13062287				HL				3	54 795 186
rs13192841			HL					6	138 008 907
rs2019960					HL	HL	HL	8	129 261 453
rs7111520						HL	HL	11	110 754 821
rs2425752			HL					20	44 135 527
HL <i>P</i> -value threshold	$5 \times 10^{-8}$	$5 \times 10^{-7}$	$5 \times 10^{-6}$	$5 \times 10^{-5}$	$5 \times 10^{-4}$	0.005	0.05	CHR	Position
rs11161570							MS	1	85 494 499
rs6603986					MS	MS	MS	1	92 789 809
rs2941584						MS		2	54 735 125
rs10496164							MS	2	68 463 624
rs3806624							MS	3	27 739 627
rs433317			MS	MS	MS	MS	MS	3	28 035 460
rs13062287						MS	MS	3	54 795 186
rs4285028							MS	3	123 143 354
rs10941508						MS	MS	5	40 494 824
rs10065637						MS	MS	5	55 474 608
rs13188158						MS		5	119 902 205
rs2064430					MS	MS	MS	6	135 684 449
rs9376268						MS		6	137 574 444
rs1002658						MS		6	138 023 277
rs2214543							MS	7	10 763 417
rs2019960		MS	MS	MS	MS	MS	MS	8	129 261 453
rs7111520			MS	MS	MS			11	110 754 821
rs715412						MS	MS	11	118 189 820
rs11172482					MS	MS		12	56 846 693
rs17119756						MS	MS	14	83 704 185
rs2725544						MS		15	46 780 189
rs13330041							MS	16	10 996 309
rs12927773							MS	16	11 311 464
rs12456021							MS	18	54 364 370
rs2425752						MS	MS	20	44 135 527
rs2248359							MS	20	52 224 925

Top: a grey box indicates that an SNP was associated with MS (at the *P*-value threshold shown in the top row), and was also associated with HL (FDR < 0.05; adjusted for the total number of SNPs that were tested in HL at the given MS threshold). Bottom: a grey box indicates that an SNP was associated with HL (at the *P*-value threshold shown in the top row), and was also associated with MS (FDR < 0.05; adjusted for the total number of SNPs that were tested in MS at the given HL threshold). Only independent SNPs are shown ( $r^2 < 0.1$ ). The HLA region is omitted.


CHR, chromosome.

nominally associated SNPs. We found 100 associated modules (with threshold of score > 3) in MS comprising 1404 genes and 4050 edges, and 100 associated modules in HL comprising 1049 genes and 3652 edges. The intersection of the HL and MS networks yielded a network of 430 genes and 1066 edges. A gene ontology (GO) analysis of this intersection network using the software binGO revealed enrichment in JUN kinase activity, antigen processing and presentation, peptidyl-tyrosine phosphorylation and lymphocyte-mediated immunity (Figure 4; Table S4, available as Supplementary data at *IJE* online). When the analysis was repeated after a seven mega-base region surrounding the HLA was masked, the antigen processing


and presentation pathway was no longer associated but JUN kinase activity, peptidyl-tyrosine phosphorylation and lymphocyte-mediated immunity remained.

### Diseasome analysis

To assess the relative position of HL and MS among other autoimmune diseases and cancers (in terms of shared genetic risk), pairwise proximities were calculated among 37 complex autoimmune diseases, solid cancers and haematological malignancies (Table 3), where proximity is a network-based relatedness measure derived from shared GWAS loci between diseases. Autoimmune diseases showed more genetic



**Figure 2.** Legend. Classical HLA alleles were imputed in each disease using SNP data. Each point in each plot represents a classical HLA allele. Axes represent the odds ratio of association for each allele in the designated disease. Protective alleles have odds ratios less than 1 (lower values on each axis) and risk alleles have odds ratios greater than 1 (high values on each axis). (A) HLA risk alleles for EBV-positive HL tend to be neutral for EBV-negative HL, while HLA risk alleles for EBV-negative HL are neutral to protective for EBV-positive HL. Some HLA alleles are protective for both diseases. (B) HLA risk alleles for EBV-positive HL are neutral or protective for MS, and HLA risk alleles for MS are neutral or protective for EBV-positive HL. There are a large number of HLA alleles which are protective for both MS and EBV-positive HL. (C) There is an overlap between HLA risk alleles for MS and EBV-negative HL, and overlap between protective alleles for MS and EBV-negative HL.




**Figure 3.** Polygenic risk scores demonstrate overlap between diseases. Hodgkin lymphoma (HL) and multiple sclerosis (MS) polygenic risk scores in HL cases, MS cases and healthy controls. A. MS genetic burden (MSGB) on y-axis, an aggregate measure of MS genetic risk across the genome of a given individual (includes human leukocyte antigen region of chromosome 6). MSGB is higher in HL cases than controls, indicating genetic overlap between HL and MS. B. HL genetic burden (HLGB) on y-axis, an aggregate measure of HL genetic risk across the genome of a given individual (includes human leukocyte antigen region of chromosome 6). HLGB is higher in MS cases than controls, indicating genetic overlap between HL and MS.

similarity to other autoimmune diseases than to solid cancers ( $P = 3.5 \times 10^{-38}$ , Figure 5A), and analogously, the individual solid cancers showed more genetic similarity to other solid cancers than to autoimmune diseases ( $P = 5.4 \times 10^{-9}$ , Figure 5C). MS was closer to other autoimmune diseases than to solid cancers ( $P = 9.2 \times 10^{-6}$ , Figure 5D).

Haematological malignancies, as a group, displayed approximately equal proximity to solid cancers and autoimmune disorders ( $P = 0.49$  for a difference, Figure 5B). However, when the haematological malignancies were considered individually, HL was closer to autoimmune diseases than to solid cancers ( $P = 0.01$ , Figure 5E). Chronic





**Figure 4.** Protein-interaction network-based pathway analysis (PINBPA) and gene ontology (GO). Four top pathways identified using GO analysis on PINBPA networks discovered in both Hodgkin lymphoma (HL) and multiple sclerosis (MS). A. Positive regulation of JUN kinase activity. B. Antigen processing and presentation of peptide antigen. C. Peptidyl-tyrosine phosphorylation. D. Lymphocyte-mediated immunity. Individual gene  $P$ -values for MS and HL are indicated when  $P < 0.05$  (\*) or when  $P < 0.1$  (‡).

lymphocytic leukaemia (CLL) was also closer to autoimmune diseases ( $P = 0.038$ , Figure S2 available as Supplementary data at *IJE* online) but also shared some loci with solid cancers. In contrast, multiple myeloma (MM) was closer to solid cancers than to autoimmune diseases ( $P = 0.08$ , Figure S2). Figure 6 is a graphical representation of the proximity network between diseases.

## Discussion

In this study, we undertook a series of analyses exploring genetic overlap between HL and MS. We found that top HL-associated SNPs were associated with MS, and conversely that top MS-associated SNPs were associated with HL. Overlap was particularly prominent in the HLA region of chromosome 6 but also applied to non-HLA loci. Genetic overlap between HL and MS was also observed in analyses of disease-specific polygenic risk scores (HLGB and MSGB) which included the HLA region. The HLGB explained

4.44% of the risk of HL and the MSGB explained 1.94% of the risk of HL. Similarly, MSGB explained 8.08% of the risk of MS and HLGB explained 2.36% of the risk for MS. Thus, the MSGB captured approximately 40% of the genetic susceptibility to HL measured by the HLGB and the HLGB captured approximately 30% of the genetic susceptibility to MS measured by the MSGB. Additionally, pathway analysis suggested shared biological pathways between HL and MS, involving a common theme of immune activation and cell proliferation, including lymphocyte-mediated immunity, positive regulation of JUN kinase activity (which plays roles in cellular response to stress, T cell differentiation, inflammation and apoptosis), peptidyl-tyrosine-phosphorylation (a non-specific intermediate step in multiple tyrosine pathways) and antigen processing and presentation.

The shared genetic element between HL and MS suggested by the present investigation is consistent with the original hypothesis of shared associations between the two conditions and with their previously observed mutual clustering within


**Table 3.** Classification of immune and neoplastic diseases from the diseasome

Autoimmune diseases	Solid cancers
Alopecia areata (AR)	Basal cell carcinoma (BCC)
Ankylosing spondylitis (AS)	Bladder carcinoma (BLC)
Behcet's disease (Beh)	Breast carcinoma (BRC)
Celiac disease (Cel)	Central nervous system cancer (CNS)
Crohn's disease (CD)	Oesophageal carcinoma (OESC)
Graves' disease (GD)	Lung adenocarcinoma (LUA)
IGA glomerulonephritis (IGA)	Lung carcinoma (LUC)
Kawasaki disease (KAW)	Melanoma (MEL)
Multiple sclerosis (MS)	Ovarian carcinoma (OVC)
Primary biliary cirrhosis (PBC)	Pancreatic carcinoma (PAC)
Psoriasis (PS)	Prostate carcinoma (PRC)
Psoriatic arthritis (PSA)	Renal cell carcinoma (RCC)
Rheumatoid arthritis (RA)	Squamous cell carcinoma (SCC)
Sclerosing cholangitis (PSC)	Stomach carcinoma (STC)
Systemic lupus erythematosus (SLE)	Thyroid carcinoma (THC)
Systemic sclerosis (SS)	
Type 1 diabetes mellitus (T1D)	
Ulcerative colitis (UC)	
Vitiligo (Vit)	
<b>Haematological cancers</b>	
Chronic lymphocytic leukemia (CLL)	
Hodgkin lymphoma (HL)	
Multiple myeloma (MM)	


families.<sup>17,18</sup> Therefore further investigation of pathogenic pathways shared by these two clinically distinct conditions, similar to those being conducted for other neurodegenerative diseases associated with cancer risk,<sup>43</sup> is warranted.

Both EBV-positive and EBV-negative HL<sup>44-46</sup> and MS<sup>47</sup> have been consistently and strongly associated with HLA alleles. Our study confirms that this locus confers the highest known effect for the three phenotypes. Interestingly, in stratified analyses the patterns of overlap with MS clearly differed between EBV-positive HL and EBV-negative HL. Risk alleles were shared between EBV-negative HL and MS, but not between EBV-positive HL and MS. These findings suggest that EBV-positive HL and EBV-negative HL may each be independently associated with MS, but via different genes.

The precise mechanisms underlying the HLA associations have not been firmly established either for HL or MS. In MS, one immune model holds that T cells, activated peripherally by an infectious agent, cross the blood-brain barrier and induce MS lesions upon reactivation by myelin fragment antigens presented in the context of HLA.<sup>48</sup> For HL, speculation has centred primarily on its presumed infectious aetiology,<sup>30,31,44</sup> with EBV present and expressing antigens with plausible pathogenic functions in all tumour cells and therefore likely playing a causative role in the EBV-positive subset of HL.<sup>49</sup> Moreover, like MS,<sup>22</sup> EBV-positive HL has been



**Figure 5.** Diseaseome analysis reveals that haematological malignancies lie somewhere between autoimmune diseases and solid cancer. A. Proximity of autoimmune diseases to other diseases. Density plots represent all possible pair-wise proximities between autoimmune diseases and solid cancers (orange), and all pair-wise proximities between autoimmune diseases and other autoimmune disease (purple). Higher degree of proximity (higher values on the x-axis) indicates more genetic similarity to autoimmune diseases. The *P*-value indicates that autoimmune diseases are closer to other autoimmune diseases than to solid cancers. B. Proximity of haematological malignancies to solid cancers (orange) and to autoimmune diseases (purple). Haematological malignancies show genetic overlap with both solid cancers and autoimmune diseases. C. Proximity of solid cancers to other solid cancers (orange) and to autoimmune diseases (purple). Solid cancers are closer to other solid cancers than to autoimmune diseases. D. Proximity of MS to all diseases. Each circle represents a disease in the diseasome. Higher degrees of proximity (higher values on x-axis) represent more genetic similarity with MS. Solid cancers are orange, autoimmune diseases are purple, HL is white. The *P*-value indicates MS is closer to autoimmune diseases than to solid cancers. E. Proximity of HL to all diseases. HL is closer to autoimmune diseases than to solid cancers.



**Figure 6.** Human disease network shows distinct autoimmune and solid cancer clusters and places hematologic cancers in context. In a network of disease proximity, constructed using systematic GWAS data, autoimmune diseases (purple) tightly cluster. Solid cancers (orange) also form a distinct cluster, but exhibit less relatedness in terms of genetic etiology than autoimmune diseases. Hematologic cancers (white) do not form a cohesive cluster and instead ranged from autoimmune related to solid cancer related. Hodgkin lymphoma (HL), in particular, appeared strongly autoimmune. See table 3 for a list of abbreviations.

associated with infectious mononucleosis caused by primary EBV infection<sup>20</sup> and with aberrant anti-EBV nuclear antigen antibody patterns, albeit different from those associated with MS.<sup>19,21</sup> Accordingly, HLA-specific variation in immune response to EBV infection may mediate the effects of the HLA associations shared by EBV-positive HL and MS. Although an analogous scenario involving an HLA-specific immune response directed against an infectious organism different from EBV may be envisioned for EBV-negative HL, no such agent has been linked to this HL subgroup<sup>50</sup> or to MS as yet.

Construction of a diseasome based on disease-gene associations<sup>42</sup> showed that the close genetic relationship between HL and the autoimmune disease MS applied to a broad spectrum of autoimmune conditions and that HL was in general closer to autoimmune diseases than to solid cancers. Importantly, the observation was not entirely explained by HLA, and the close relationship between HL and autoimmune conditions remained when the diseasome analysis was repeated after masking a seven mega-base region surrounding

the HLA region. In line with this, there is evidence to suggest that the risk of HL is increased in patients with autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.<sup>51,52</sup> In the absence of evidence of familial clustering of HL and autoimmune diseases,<sup>53</sup> mechanisms such as chronic immune stimulation and/or immune-modulating treatment have been considered the most plausible explanations for the association. However, the present analyses suggest that shared genetic constitution may also contribute to the increased prevalence of HL among patients with autoimmune diseases (though an interaction between genetics and immune-modulating treatment is also a possibility). Indeed, our approach of combining GWAS data may prove more efficient in demonstrating overlapping pathogenic pathways between diseases than traditional epidemiological analytical designs, which may suffer from inadequate statistical power.

Besides HL, the diseasome analysis also included two other haematological malignancies. Among these, CLL was also closer to autoimmune diseases whereas multiple



myeloma showed similarity to solid cancers. CLL belongs to the group of non-Hodgkin lymphomas<sup>54</sup> and, although strong associations between autoimmune disorders and CLL per se have not been noted,<sup>55</sup> an increased risk of the combined group of non-Hodgkin lymphomas among patients with various autoimmune diseases is well documented in the literature.<sup>56</sup>

The main limitation of the present study was the uneven distribution of HL and MS patients with GWAS data and the lack of independent validation datasets. These limitations likely do not affect the disease results which are based on multiple GWAS in each disease and are robust to the removal of any single GWAS. However, SNP-level summary data for other autoimmune diseases and other cancers would have allowed assessment of polygenic risk scores and specific genetic overlap between other pairs of diseases that were closely associated in the diseaseome, i.e. in the same way that the genetic overlap between HL and MS was assessed. Perhaps the diseaseome analysis will provide impetus for further collaborative meta-analyses of haematological malignancies and autoimmune diseases.

In summary, this study demonstrated commonalities in the genetic susceptibility to HL and MS as evidenced by analyses of individual SNPs, polygenic risk scores and protein-interaction networks. Diseaseome analysis further suggested that HL shares a genetic architecture more similar to that of autoimmune diseases than to solid cancers. We speculate that autoimmune diseases and HL are different manifestations of a shared underlying genetic syndrome.

## Supplementary Data

Supplementary data are available at *IJE* online.

## Funding

Funding for this project was obtained from the Nordic Cancer Union (16-02-D to H.H.), the Lundbeck Foundation (R19-A2364 to H.H.), the Danish Cancer Research Foundation (41-08 to H.H.), the National Institutes of Health (CA110836 to W.C.; HD0433871, CA129045, and CA40046 to K.O.; CA55727 to L.L.R.; CA58839 to T.M.M.), the United States Army Medical Research and Materiel Command (Department of Defense PR054600 to W.C.), the American Cancer Society Illinois Division (to K.O.), the American Lebanese Syrian Associated Charities (to L.L.R.), the Leukemia & Lymphoma Society (TR6137-07 to W.C.), the Cancer Research Foundation (to K.O.), the National Cancer Institute Surveillance Epidemiology and End Results Population-based Registry Program at the National Institutes of Health in the Department of Health and Human Services (R01-NS-026799 to J.R.O., N01-PC-35139 to W.C. and N01-PC-35136 to the Cancer Prevention Institute of California), the National Cancer Institute (263-MQ-417755 to S.L.G.), the Leukemia Lymphoma Research and Kay Kendall Leukemia fund (grant 12022 to R.F.J.), the California Cancer Registry and the Dutch Cancer Society (KWF grants RUG 2009-

4313 and RUG 2014-6698 to A.v.d.B.), the National Science Foundation (Graduate Research Fellowship Grant 1144247 to D.S.H.) and the Center for Neuroengineering and Therapeutics at the University of Pennsylvania (P.K.).

## Acknowledgments

We thank the Childhood Cancer Survivor Study (National Cancer Institute grant U24 CA 55727) for the Hodgkin Lymphoma data, and the International Multiple Sclerosis Genetics Consortium and the Wellcome Trust Case-Control Consortium for the multiple sclerosis data. We would like to thank Hans-Olov Adami, David Conti, Arjan Diepstra, Bengt Glimelius, Annette Lake, Dorothy Montgomery, Les Robison, Malcolm Taylor, and Maria Timofeeva for data accrual, sample handling and analysis of Hodgkin lymphoma data. We would like to thank Stacy J. Caillier and Sarah Beth Hill for assistance with figure creation.

## Author contributions

Contributions: P.K., W.C., D.S.H., S.E.B., J.D.M., J.R.O. and H.H. designed the experiment. P.K., D.S.H., L.M., L.D., T.M., J.M.M., A.L., P.A.G., M.D.S., D.L. and J.D.M. analysed the data. A.v.d.B., S.L.G., K.E.S., T.M.M., S.d.S., A.N., S.L.H., P.C., M.M., L.F., A.S., M.D.S., S.B., M.M., K.O., R.J., J.D.M., J.R.O. and H.H. contributed reagents, materials and analysis tools. P.K., W.C., D.S.H., S.E.B., P.A.G., R.J., J.D.M., J.R.O. and H.H. wrote the paper. All authors read and approved the final manuscript.

**Conflict of interest:** None declared.

## References

- Stein H. Hodgkin lymphoma - Introduction. In: Swerdlow SH, Campo E, Harris NL *et al.* (eds). *Tumours of Haematopoietic and Lymphoid Tissues*. Lyon, France: IARC Press, 2008.
- MacMahon B. Epidemiology of Hodgkin's disease. *Cancer Res* 1966;26:1189-.
- Mueller N, Grufferman S. Hodgkin lymphoma. In: Schottenfeld D, Fraumeni JJr (eds). *Cancer Epidemiology and Prevention*. 3rd edn. Oxford, UK: Oxford University Press, 2006.
- MacMahon B. Epidemiological evidence of the nature of Hodgkin's disease. *Cancer* 1957;10:1045-13.
- Correa P, O'Connor GT. Epidemiologic patterns of Hodgkin's disease. *Int J Cancer* 1971;8:192-201.
- Hauser S, Goodin DS. Multiple sclerosis and other demyelinating diseases. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson L, Loscalzo J (eds). *Harrison's Principles of Internal Medicine*. 18th edn. New York, NY: McGraw-Hill, 2012.
- Newell GR. Etiology of multiple sclerosis and Hodgkin's disease. *Am J Epidemiol* 1970;91:11-22.
- Bahmanyar S, Montgomery SM, Hillert J, Ekblom A, Olsson T. Cancer risk among patients with multiple sclerosis and their parents. *Neurology* 2009;72:1170-77.
- Bernard SM, Cartwright RA, Darwin CM *et al.* Hodgkin's disease: case control epidemiological study in Yorkshire. *Br J Cancer* 1987;55:85-90.
- Koch-Henriksen N, Bronnum-Hansen H, Stenager E. Underlying cause of death in Danish patients with multiple sclerosis: results

- from the Danish Multiple Sclerosis Registry. *J Neurol Neurosurg Psychiatry* 1998;65:56–59.
11. Lebrun C, Debouverie M, Vermersch P *et al.* Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. *Mult Scler* 2008;14:399–405.
  12. Midgard R, Glattre E, Gronning M, Riise T, Edland A, Nyland H. Multiple sclerosis and cancer in Norway. A retrospective cohort study. *Acta Neurol Scand* 1996;93:411–15.
  13. Moller H, Kneller RW, Boice JD Jr, Olsen JH. Cancer incidence following hospitalization for multiple sclerosis in Denmark. *Acta Neurol Scand* 1991;84:214–20.
  14. Palo J, Duchesne J, Wikstrom J. Malignant diseases among patients with multiple sclerosis. *J Neurol* 1977;216:217–22.
  15. Sadovnick AD, Eisen K, Ebers GC, Paty DW. Cause of death in patients attending multiple sclerosis clinics. *Neurology* 1991;41:1193–96.
  16. Vineis P, Crosignani P, Vigano C *et al.* Lymphomas and multiple sclerosis in a multicenter case-control study. *Epidemiology* 2001;12:134–35.
  17. Hjalgrim H, Rasmussen S, Rostgaard K *et al.* Familial clustering of Hodgkin lymphoma and multiple sclerosis. *J Natl Cancer Inst* 2004;96:780–84.
  18. Landgren O, Kerstann KF, Gridley G *et al.* Re: Familial clustering of Hodgkin lymphoma and multiple sclerosis. *J Natl Cancer Inst* 2005;97:543–44.
  19. Levin LI, Munger KL, Rubertone MV *et al.* Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. *JAMA* 2005;293:2496–500.
  20. Hjalgrim H, Askling J, Rostgaard K *et al.* Characteristics of Hodgkin's lymphoma after infectious mononucleosis. *N Engl J Med* 2003;349:1324–32.
  21. Levin LI, Chang ET, Ambinder RF *et al.* Atypical prediagnosis Epstein-Barr virus serology restricted to EBV-positive Hodgkin lymphoma. *Blood* 2012;120:3750–55.
  22. Nielsen TR, Rostgaard K, Nielsen NM *et al.* Multiple sclerosis after infectious mononucleosis. *Arch Neurol* 2007;64:72–75.
  23. Monnereau A, Glaser SL, Schupp CW *et al.* Exposure to UV radiation and risk of Hodgkin lymphoma: a pooled analysis. *Blood* 2013;122:3492–99.
  24. Beretich BD, Beretich TM. Explaining multiple sclerosis prevalence by ultraviolet exposure: a geospatial analysis. *Mult Scler* 2009;15:891–98.
  25. Enciso-Mora V, Broderick P, Ma Y *et al.* A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). *Nat Genet* 2010;42:1126–30.
  26. Cozen W, Li D, Best T *et al.* A genome-wide meta-analysis of nodular sclerosing Hodgkin. *Blood* 2012; 119:469–75.
  27. Urayama KY, Jarrett RF, Hjalgrim H *et al.* Genome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroups. *J Natl Cancer Inst* 2012;104:240–53.
  28. Sawcer S, Hellenthal G, Pirinen M *et al.* Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. *Nature* 2011;476:214–19.
  29. Isobe N, Gourraud PA, Harbo HF *et al.* Genetic risk variants in African Americans with multiple sclerosis. *Neurology* 2013 July 16;81(3):219–27.
  30. Niens M, Jarrett RF, Hepkema B *et al.* HLA-A\*02 is associated with a reduced risk and HLA-A\*01 with an increased risk of developing EBV+ Hodgkin lymphoma. *Blood* 2007;11:3310–15.
  31. Hjalgrim H, Rostgaard K, Johnson PC *et al.* HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T cell response in EBV-related Hodgkin lymphoma. *Proc Natl Acad Sci U S A* 2010;107:6400–05.
  32. Baranzini SE, Khankhanian P, Patsopoulos NA *et al.* Network-based multiple sclerosis pathway analysis with GWAS data from 15,000 cases and 30,000 controls. *Am J Hum Genet* 2013;92: 854–65
  33. Best T, Li D, Skol AD *et al.* Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma. *Nat Med* 2011;17:941–43.
  34. Cozen W, Timofeeva MN, Li D *et al.* A meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locus. *Nat Commun* 2014;5:3856.
  35. Goris A, van SJ, Diekstra F *et al.* No evidence for shared genetic basis of common variants in multiple sclerosis and amyotrophic lateral sclerosis. *Hum Mol Genet* 2014;23:1916–22.
  36. Gourraud PA, McElroy JP, Caillier SJ *et al.* Aggregation of multiple sclerosis genetic risk variants in multiple and single case families. *Ann Neurol* 2011;69:65–74.
  37. Isobe N, Damotte V, Lo R *et al.* Genetic burden in multiple sclerosis families. *Genes Immun* 2013;14:434–40.
  38. Goh KI, Cusick ME, Valle D, Childs B, Vidal M, Barabasi AL. The human disease network. *Proc Natl Acad Sci U S A* 2007;104:8685–90.
  39. Wang K, Ng SK, McLachlan GJ. Clustering of time-course gene expression profiles using normal mixture models with autoregressive random effects. *BMC Bioinformatics* 2012;13:300.
  40. Himmelstein D, Khankhanian P, Baranzini SE. A human disease network from GWAS loci. *Zenodo* 2015.
  41. Himmelstein D. Extracting disease-gene associations from the GWAS Catalog. *ThinkLab* 2015.
  42. Welter D, MacArthur J, Morales J *et al.* The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. *Nucleic Acids Res* 2014;42(Database issue):D1001–D1006.
  43. Plun-Favreau H, Lewis PA, Hardy J, Martins LM, Wood NW. Cancer and neurodegeneration: between the devil and the deep blue sea. *PLoS Genet* 2010;6:e1001257.
  44. Huang X, Kushekhar K, Nolte I *et al.* HLA associations in classical Hodgkin lymphoma: EBV status matters. *PLoS One* 2012;7:e39986.
  45. Niens M, van den Berg A, Diepstra A *et al.* The human leukocyte antigen class I region is associated with EBV-positive Hodgkin's lymphoma: HLA-A and HLA complex group 9 are putative candidate genes. *Cancer Epidemiol Biomarkers Prev* 2006;15:2280–84.
  46. Johnson PC, McAulay KA, Montgomery D *et al.* Modeling HLA associations with EBV-positive and -negative Hodgkin lymphoma suggests distinct mechanisms in disease pathogenesis. *Int J Cancer* 2015;137:1066–75.
  47. Beecham AH, Patsopoulos NA, Xifara DK *et al.* Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. *Nat Genet* 2013;45:1353–60.



48. Lang HL, Jacobsen H, Ikemizu S *et al.* A functional and structural basis for TCR cross-reactivity in multiple sclerosis. *Nat Immunol* 2002;**3**:940–43.
49. Kuppers R. The biology of Hodgkin's lymphoma. *Nat Rev Cancer* 2009;**9**:15–27.
50. Jarrett RF. Viruses and Hodgkin's lymphoma. *Ann Oncol* 2002;**13**(Suppl 1):23–29.
51. Fallah M, Liu X, Ji J, Forsti A, Sundquist K, Hemminki K. Hodgkin lymphoma after autoimmune diseases by age at diagnosis and histological subtype. *Ann Oncol* 2014;**25**: 1397–404.
52. Landgren O, Caporaso NE. New aspects in descriptive, etiologic, and molecular epidemiology of Hodgkin's lymphoma. *Hematol Oncol Clin North Am* 2007;**21**:825–40.
53. Landgren O, Engels EA, Pfeiffer RM *et al.* Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. *J Natl Cancer Inst* 2006;**98**:1321–30.
54. World Health Organization. *Classification of Tumours of Haematopoietic and Lymphoid Tissues*. Lyon, France: IARC, 2008.
55. Landgren O, Engels EA, Caporaso NE *et al.* Patterns of autoimmunity and subsequent chronic lymphocytic leukemia in Nordic countries. *Blood* 2006;**108**:292–96.
56. Baecklund E, Smedby KE, Sutton LA, Askling J, Rosenquist R. Lymphoma development in patients with autoimmune and inflammatory disorder - what are the driving forces? *Semin Cancer Biol* 2014;**24**:61–70.